Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)

被引：66
|
作者：
Demeter, LM
Shafer, RW
Meehan, PM
Holden-Wiltse, J
Fischl, MA
Freimuth, WW
Para, MF
Reichman, RC
机构：
[1] Univ Rochester, Infect Dis Unit, Sch Med & Dent, Rochester, NY 14642 USA
[2] Stanford Univ, Palo Alto, CA 94304 USA
[3] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
[4] Univ Miami, Miami, FL 33152 USA
[5] Pharmacia & Upjohn Inc, Kalamazoo, MI 49001 USA
[6] Ohio State Univ, Columbus, OH 43210 USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2000年 / 44卷 / 03期
关键词：
D O I：
10.1128/AAC.44.3.794-797.2000
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance, were the predominant reverse transcriptase mutations. P236L, which confers DLV resistance but hypersensitivity to other NNRTIs, developed in <10% of isolates.
引用
收藏
页码：794 / 797
页数：4
相关论文
共 50 条
  • [41] Mutations in the primer grip of human immunodeficiency virus type 1 reverse transcriptase impair proviral DNA synthesis and virion maturation
    Yu, Q
    Ottmann, M
    Pechoux, C
    Le Grice, S
    Darlix, JL
    JOURNAL OF VIROLOGY, 1998, 72 (09) : 7676 - 7680
  • [42] Major Drug Resistance Mutations on Reverse Transcriptase Gene in Human Immunodeficiency Virus Type-1 in Indonesia: A Systematic Review
    Nurjannah
    Jayanti, Sri
    Tanoerahardjo, Francisca Srioetami
    Al Musyahadah, Ummu Syauqah
    Sukowati, Caecilia Hapsari Ceriapuri
    Massi, Muhammad Nasrum
    CURRENT HIV/AIDS REPORTS, 2024, 21 (02) : 31 - 39
  • [43] INTERACTIONS BETWEEN DRUG-RESISTANCE MUTATIONS IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE
    LARDER, BA
    JOURNAL OF GENERAL VIROLOGY, 1994, 75 : 951 - 957
  • [44] Major Drug Resistance Mutations on Reverse Transcriptase Gene in Human Immunodeficiency Virus Type-1 in Indonesia: A Systematic Review
    Sri Nurjannah
    Francisca Srioetami Jayanti
    Ummu Syauqah Tanoerahardjo
    Caecilia Hapsari Ceriapuri Al Musyahadah
    Muhammad Nasrum Sukowati
    Current HIV/AIDS Reports, 2024, 21 : 31 - 39
  • [45] A mutation in the 3′ region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance
    Harrigan, PR
    Salim, M
    Stammers, DK
    Wynhoven, B
    Brumme, ZL
    McKenna, P
    Larder, B
    Kemp, SD
    JOURNAL OF VIROLOGY, 2002, 76 (13) : 6836 - 6840
  • [46] Mutations in the human immunodeficiency virus type 1 reverse transcriptase gene observed in stavudine and didanosine strains obtained by in vitro passages
    Bossi, P
    Yvon, A
    Mouroux, M
    Huraux, JM
    Agut, H
    Calvez, V
    RESEARCH IN VIROLOGY, 1998, 149 (06): : 355 - 361
  • [47] Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations - Reply
    Young, B
    Kuritzkes, DR
    JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (02): : 570 - 571
  • [48] Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency
    Nikolenko, GN
    Svarovskaia, ES
    Delviks, KA
    Pathak, VK
    JOURNAL OF VIROLOGY, 2004, 78 (16) : 8761 - 8770
  • [49] Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase
    Schuurman, R
    Demeter, L
    Reichelderfer, P
    Tijnagel, J
    de Groot, T
    Boucher, C
    JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (07) : 2291 - 2296
  • [50] Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1
    Hofman, MJ
    Higgins, J
    Matthews, TB
    Pedersen, NC
    Tan, C
    Schinazi, RF
    North, TW
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (09) : 3483 - 3490
12345